# LEVOSIMENDAN to Facilitate Weaning From ECMO in Severe Cardiogenic Shock Patients

> **NCT04728932** · PHASE3 · COMPLETED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 206 (actual)

## Conditions studied

- Cardiogenic Shock
- Extracorporeal Membrane Oxygenation Complication

## Interventions

- **DRUG:** Levosimendan
- **DRUG:** Placebo of Levosimendan

## Key facts

- **NCT ID:** NCT04728932
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-27
- **Primary completion:** 2024-11-09
- **Final completion:** 2024-11-09
- **Target enrollment:** 206 (ACTUAL)
- **Last updated:** 2025-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04728932

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04728932, "LEVOSIMENDAN to Facilitate Weaning From ECMO in Severe Cardiogenic Shock Patients". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT04728932. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*